PTCTPTC Therapeutics, Inc.
$64.70+7.0% 1Y
$64.70
$57.8452 weeks$86.25
The financials
PTC Therapeutics, Inc. by the numbers
PTC Therapeutics, Inc. (PTCT) reported revenue of $361M in Q2 2026 (quarter ended Jun 30, 2026), up 102% from the same quarter a year earlier. That came with net income of $83M (23% of revenue). For the full year FY2025, revenue was $1.73B (+115% year on year) and net income $683M. Its largest product in Q2 2026 was Sephience at $128M, 38% of the disclosed total, ahead of Royalty at 21%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $361M | $179M | +102% |
| Operating income | $149M | −$35M | to a profit |
| Net income | $83M | −$65M | to a profit |
| Diluted EPS | $0.92 | −$0.83 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Sephience | $128M | 38% |
| Royalty | $71M | 21% |
| Collaboration And License | $51M | 15% |
| Translarna | $42M | 13% |
| Emflaza | $25M | 7.3% |
| Upstaza And Kebilidi | $11M | 3.3% |
| Other Products | $9.5M | 2.8% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $336.8M (+33%)
Collaboration And License grew +1620% year on yearEmflaza -32% year on year
Segment Latestquarter on quarteryear on year
- Sephience$127.5M$127.5Mquarter on quarter +14%year on year n/a+14%n/a
- Royalty$71.1M$71.1Mquarter on quarter +52%year on year +23%+52%+23%
- Collaboration And License$50.6M$50.6Mquarter on quarter +35281%year on year +1620%+35281%+1620%
- Translarna$42.2M$42.2Mquarter on quarter -28%year on year -29%-28%-29%
- Emflaza$24.6M$24.6Mquarter on quarter +15%year on year -32%+15%-32%
- Upstaza And Kebilidi$11.2M$11.2Mquarter on quarter +272%year on year -6.1%+272%-6.1%
- Other Products$9.5M$9.5Mquarter on quarter -13%year on year -11%-13%-11%